Gynecologic Oncology

Article	Citations
Editorial board	156
Physical activity and lower extremity lymphedema among endometrial cancer survivors: A population-based cross-sectional study	104
Racial disparities in human papillomavirus vaccination rates and correlation with cervical cancer stage at diagnosis: A retrospective analysis	87
ChatGPT vs Google: Understanding a patient's perspective on their cancer diagnosis, recommended treatment, and survival outcomes	75
Endometrial stripe thickness at the time of diagnosis of uterine papillary serous carcinoma in black patients (2137)	73
Prediction of ovarian cancer with deep machine-learning and alternative splicing (2167)	66
The impact of bowel preparation on surgical site infection rates in gynecologic oncology surgery, post-hoc analysis from a randomized controlled trial (550)	65
Short-term hormone replacement therapy in BRCA mutation carriers and risk of breast cancer: A nationwide study in Korea (1155)	64
Multi-omic and clinical data analysis of pre-menopausal women under 45 years of age diagnosed with endometrial cancer and enrolled in the ASAP trial (2154)	62
Adverse postoperative outcomes associated with perioperative blood transfusion in gynecologic oncology surgery: a National Surgical Quality Improvement Program analysis (467)	59
The role of adjuvant radiation therapy in older patients with node-positive vulvar cancer: A national cancer database analysis	58
Pattern of recurrence and survival: Comparative analysis of robotic radical hysterectomy with uterine manipulator versus without uterine manipulator and or vaginal cerclage in treatment of stage IB ce	57
Mitigating disparity? Recurrence rates and palliative care referrals by race and ethnicity across a large urban health system (514)	55
Ovarian and uterine carcinosarcoma cell lines show preclinical sensitivity to BAY 1895344, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor (011)	55
Development of a molecular and clinical evidence-based algorithm for selecting optimal precision therapeutic strategy for patients with ovarian carcinoma (157)	52
Role of lymphadenectomy for apparent early-stage low-grade serous ovarian carcinoma (529)	51
Effect of sentinel lymph node isolated tumor cells on recurrence free survival in patients with mismatch repair proficient vs. deficient stage I/II endometrioid endometrial adenocarcinoma (173)	51
Impact of increased cycles of neoadjuvant chemotherapy on interval debulking surgery outcomes (541)	47
Improving the cancer survivorship journey: Developing a survivorship care transition model for rural and underserved low risk breast and gynecologic cancer patients (511)	46
Impact of venous thromboembolism on timing and outcomes of interval debulking surgery among patients treated with neoadjuvant chemotherapy for advanced ovarian cancer (370)	45
Ketogenic Diet Promotes Epithelial Ovarian Cancer Progression and Alters Tumor Gene Expression in-vivo (104)	45
Highlights from the 2022 Society of Gynecologic Oncology Annual Meeting on Women's Cancer	45
Molecular profiling of gestational trophoblastic neoplasia: Identifying therapeutic targets (167)	43
Taking the ‘first steps’ to a healthier lifestyle: The initial acceptability and feasibility of a health behavior intervention for endometrial cancer survivors with obesity and their social support ne	42
Diversifying clinical trials: Does presentation at gynecologic oncology tumor board increase equitable access to clinical trials for Black and LatinX patients? (2205)	40

TOGETHER Care: PatienT-tailOred GynEcologic Oncology posT discHargE caRe (290)	40
Leave it in the past: Primary treatment modality for high-grade epithelial ovarian cancer does not affect secondary cytoreduction outcomes (173)	40
Food deserts, endometrial cancer survivors, and healthy food access: Is it equitable in rural America? – A geospatial analysis (2127)	40
Patient-reported post-discharge opioid use after abdominal gynecologic surgery in an Enhanced Recovery After Surgery (ERAS) program (004)	40
Impact of COVID-19 on gynecologic oncology patients: an SGO COVID-19 and Gynecologic Cancer Registry study (050)	39
Predictors of long-term response in prospective phase II trial of levonorgestrel intrauterine device for atypical hyperplasia and early endometrial cancer (1247)	39
Creation of a surgical service line to treat patients with recurrent gynecologic cancer with curative intent: Complex oncologic multidisciplinary pelvic surgery (COMPS) (559)	39
Clinical impact of low-volume lymph node metastases in early- stage cervical cancer: A comprehensive meta-analysis (504)	38
Prognostic factors of survival in women with recurrent platinum-resistant epithelial ovarian cancer (1171)	38
Metastatic site-specific prognosis of women with stage IVB cervical cancer (345)	37
Uterine cancer incidence overtakes colorectal cancer, disproportionately impacting minority women in the United States	36
Perioperative outcomes after interval cytoreductive surgery and primary cytoreductive surgery for advanced epithelial ovarian cancer in Australia: A National Gynae-Oncology Registry (NGOR) study	36
Quantifying opportunities to reduce high-grade serous ovarian cancer via opportunistic salpingectomy	35
Molecular testing in the upfront setting for high-grade endometrial cancer: How are we doing?	35
Ovarian-Adnexal Reporting and Data System (O-RADS) for adnexal masses: Are we hitting the mark?	34
Investigating the role of the poly (ADP-ribose) polymerase enzyme family in cervical cancer pathogenesis	34
A phase I, first-in-human, dose escalation and expansion study to evaluate the safety and tolerability of XmAb541 (Claudin 6 x CD3) T-cell engaging bispecific antibody in advanced solid tumors	34
Obesity and ovarian cancer: Leveraging real-world data for incidence and outcomes using a multicenter nationwide electronic database	34
Clear cell carcinoma of cervix and vagina: A review of 63 cases in the post-diethylstilbestrol era	33
Trends in FDA approval of novel therapies in women's cancer: A study of the last 25 years	33
(ENCORE) Long-term safety and efficacy of selinexor maintenance treatment in patients with TP53 wild-type advanced or recurrent endometrial cancer: Follow-up subgroup analysis of the ENGOT-EN5/GOG-305	32
2025 Annual Meeting on Women's Cancer – SGO Meeting Insights	32
Cytology-negative, non-myoinvasive stage IC serous endometrial cancer: Assessment of adjuvant chemotherapy omission	31
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery	31
The promise and perils of biomarker testing in gynecologic cancers	31
Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes	31
Endometrial cancer survivors' perceptions of their cardiovascular disease risk (results from WF-1804CD AH-HA)	31
Prognosis of patients who become pregnant after achieving a complete response with fertility-sparing treatment in early endometrial cancer: A Gynecologic Oncology Research Investigators Collaboration	31
Elucidating the influences of social determinants of health on perceived overall health among African American/Black and Hispanic ovarian cancer survivors using the NIH All of Us Research Program	30
Defining “enlarged” sentinel lymph nodes in the setting of endometrial cancer: What is the size cut-off?	30
RE1 transcription factor is decreased in endometrial cancer	29
Concurrent POLE hotspot mutations and mismatch repair deficiency in endometrial cancer: Defining cancer drivers	29
Uterine cancer among Asian Americans: Disparities & clinical characteristics and disease presentations	29
Patients with lower health literacy are less likely to be identified as eligible for hereditary cancer genetic testing by a digital risk stratification tool: An urban academic gynecologic oncology cli	29
Spatial RNA sequencing supports programmed death ligand 2 (PD-L2) as a potential immunotherapy target in high-grade serous ovarian carcinoma	28
Peritoneal washing analysis in endometrial cancer: Does somatic mutation detection with panel sequencing build upon traditional cytologic analysis?	28
The implementation of an electronic symptom management system to monitor the severity of symptoms in gynecologic oncology patients initiating chemotherapy: A multicenter evaluation	27
Themes, perspectives, and educational quality of content related to Pap smears on TikTok and YouTube	27
Outcomes of groin recurrence in vulvar cancer after primary treatment with a sentinel lymph node procedure	26
The Doc versus the Bot: A pilot study to assess the quality and accuracy of physician and chatbot responses to clinical questions in gynecologic oncology	26
COPANIRA: Phase Ib trial of copanlisib (PI3K inhibitor) and niraparib (PARP inhibitor) in recurrent ovarian and endometrial cancer	26
Defects in mismatch repair promote disease character likeness amongst Black and White women with endometrial cancer	26
The outcome of waiting for radiotherapy in locally advanced cervical cancer	26
The use of pedometers to assess patient ambulation following gynecologic oncology surgery: A prospective observational study	26
Outcomes among patients with chronic kidney disease undergoing HIPEC for ovarian cancer	26
Oncologic outcomes and adverse events with immunotherapy treatment among frail patients with gynecologic cancers	25
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo	25
Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer – An NRG/GOG study	25
Accuracy of patient-reported gynecologic cancer diagnoses and procedures at a large academic medical center	25
What are the CA-125 testing rates and their clinical implications among patients with advanced ovarian cancer treated in real-world community practice?	25

Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations	25
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study	25
Home-based treatment of low-risk gestational trophoblastic neoplasia with 8-day methotrexate/folinic acid	25
The 15th Biennial Rivkin Center ovarian cancer research symposium	25
Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma	25
Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies	24
Corrigendum to “Chemotherapy response score (CRS) as a surrogate marker for homologous recombination deficiency (HRD) based on loss of heterozygosity (LOH) in high grade serous ovarian cancer (HGSOC)	24
Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III tria	24
Combination of BVAC-C and durvalumab in recurrent or metastatic cervical cancer: A phase II study	24
Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021,	24
Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group	24
CRABP2 – A novel biomarker for high-risk endometrial cancer	24
Retrospective analysis of clinical features and fertility outcomes with fertility-sparing treatment of placental site trophoblastic tumor	24
Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125	24
Diagnostic accuracy of sentinel lymph node frozen section analysis in patients with early-stage cervical cancer: A systematic review and meta-analysis	23
Trial in progress: A phase two trial of nirogacestat, a gamma-secretase inhibitor, in patients with recurrent ovarian granulosa cell tumors (NCT05348356) (1284)	23
The role of neoadjuvant chemotherapy in advanced-stage clear cell ovarian cancer: A GCIG multi-institutional retrospective cohort study	23
Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials	23
Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203	23
Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial	22
Clinical trial screening in gynecologic oncology: Defining the need and identifying best practices	22
Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6)	22
Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs	22
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer	22
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer	22
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas	22
Liquid biopsy for advanced endometrial cancer: Prognostic value of plasma circulating DNA fraction in real-world settings (1320)	22
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial	22
Molecular comparison reveals distinct transcriptomic differences between uterine carcinosarcoma and papillary serous carcinoma distinguishable by DNA damage	21
Recurrence and survival in endometrioid endometrial cancer - a population-based cohort study	21
Utilization of guideline-concordant risk reducing gynecologic cancer surgery in the US	21
Management of chemotherapy hypersensitivity reactions and desensitization: An SGO clinical practice statement	21
Neoadjuvant chemotherapy in advanced stage endometrial cancer: A diverse, urban health system's experience	21
Immunohistochemistry for mismatch repair protein expression in endometrial intraepithelial neoplasia is cost effective to diagnose Lynch Syndrome at low population prevalence	21
Implementing non-invasive biospecimen collection in gynecologic oncology: Insights from a prospective gut microbiome feasibility study	21
Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility	21
Gynecologic cancers: Molecular and tumor-agnostic targets across ages and races	21
Age-specific incidence and survival of uterine sarcoma by histotype, race, and ethnicity in the United States, 2000–2019	20
A global, phase 1/2 study of DB-1311/BNT324 (a novel B7H3 ADC) monotherapy in patients with previously treated advanced cervical cancer or platinum-resistant recurrent ovarian cancer: Outcomes by prio	20
A retrospective study on treatment outcomes and adverse events in premenopausal patients treated with radiotherapy for cervical cancer	20
Impact of continuing education and a multi-center QI initiative on germline/HRD testing in the context of recent PARP inhibitor label changes in ovarian cancer	20
The BHFS study (Better, Harder, Faster, Stronger): Does neoadjuvant chemotherapy improve fitness for surgery?	20
Healthcare resource utilisation and costs associated with the management of locally advanced or persistent, recurrent/metastatic cervical cancer – Findings from the TRACCER real-word study in Portugal	20
Mirvetuximab resistance differentially alters paclitaxel sensitivity in platinum-resistant high-grade serous ovarian cancer	20
Integration of HPV DNA as a biomarker for progression risk in CIN-2: A pilot cohort study	20
PARPA-293-003: A phase 1a/1b, multicenter, open-label study of NMS-03305293 (itareparib), a non-trapping PARP1-selective inhibitor, in combination with topotecan in patients with recurrent platinum-re	20
Implementation and evaluation of LEAD: A pilot cohort to improve opportunity and mentorship among trainees pursuing gynecologic oncology	20
Implementation of INTERLACE induction chemotherapy protocol for locally advanced cervical cancer in a Canadian high-volume academic center: A single institution experience	20
Local delivery, lasting impact: Intraperitoneal administration of natural killer cell engagers outperform subcutaneous dosing in a xenogeneic model of ovarian cancer	20
Clinical characteristics and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma confirmed by central pathologic review: A multi-institutional retrospective study fr	19
Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression	19
Efficacy and safety of tisotumab vedotin versus investigator's choice of chemotherapy in second-line or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG-3057): A global,	19
Cancer center case volume is associated with differences in the effectiveness of neoadjuvant chemotherapy for advanced-stage epithelial ovarian cancer	19
Association of neighborhood socioeconomic disadvantage with perioperative outcomes in endometrial cancer patients	19
Profiling the immune landscape in mucinous ovarian carcinoma	19
Response to Alexandre Andre B A da Costa et al.	19
Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants	19
Sensitivity of HER2-low uterine carcinosarcoma organoids to the antibody-drug conjugate, trastuzumab deruxtecan	19
Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/	19
The impact of age on therapeutic choices and outcomes in platinum-resistant ovarian cancer	19
Editorial board	19
Editorial board	19
Characteristics and factors associated with mortality among cervical cancer patients undergoing palliative care	19
Disease progression, survival, and molecular disparities among Black and White patients with endometrioid endometrial carcinoma in real-world registries and legacy NRG oncology phase III trials	19
Single nucleotide polymorphisms associated with cervical cancer susceptibility in Georgian women	19
Improving breast cancer risk detection via digital genetic screening in an underserved population	19
3D organoid models for predicting drug response in platinum-sensitive, high-grade serous ovarian cancer	18
Progression-free and overall survival of sequential platinum, taxane, and bevacizumab followed by immunotherapy may be equivalent to concurrent chemotherapy and immunotherapy among patients with recur	18
Feasibility of laparoscopic visceral-peritoneal debulking among patients with stage III–IV ovarian cancer: The ULTRA-LAP Pilot Trial	18
Patterns of recurrence and outcomes in vulvar extramammary Paget's disease	18
Thoracic epidural analgesia in Gynecologic Oncology ERAS: A waste of time or time to consider it as a standard of care? (2162)	18
The amount of preoperative endometrial tissue surface in relation to final endometrial cancer classification	18
The effects of a nurse-led couples intervention on marital quality of couples with gynecological cancer: A clinical randomized controlled trial	18
Surgical skill and oncological outcome of laparoscopic radical hysterectomy: JGOG1081s-A1, an ancillary analysis of the Japanese Gynecologic Oncology Group Study JGOG1081	18
Assessing the readability of online health information regarding treatment modalities for gynecologic cancer patients	18
Frailty does not completely explain racial disparities in postoperative outcomes after ovarian cancer debulking	18
A phase II study of avutometinib and defactinib in advanced or recurrent gynecologic mesonephric cancer: Interim results	18
Utilizing the KELIM score and the chemo-response score to predict chemosensitivity in ovarian cancer (1212)	18
Endometrial cancer recurrence after the use of an intrauterine manipulator during laparoscopic surgery: A retrospective cohort study (1216)	18
Cervical adenocarcinoma risk stratification using histotype and invasion pattern: a multicenter retrospective study by the KAMOGAWA Study Group	18

Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts	18
Examining health-related quality of life outcomes among older patients with advanced ovarian cancer treated with niraparib first-line maintenance therapy in context with efficacy and safety findings:	18
Gamma secretase inhibitors, in combination with cytotoxic agents, decrease migration and invasion of uterine leiomyosarcoma	18
Financial toxicity among gynecologic oncology surgical patients	18
Safety and feasibility of same day discharge for robotic hysterectomy and staging for endometrial cancer	18
Implementing guidelines for risk-stratified thromboprophylaxis among gynecologic oncology patients: A quality improvement initiative	18
Health care services burden in ovarian cancer patients receiving PARP inhibitor maintenance treatment (377)	18
Cognitive outcomes after premenopausal risk-reducing Salpingo-oophorectomy: The role of hormone therapy	18
Surgical universal euglycemic attainment during recovery (SUGAR) initiative: Sweet results through quality improvement (286)	17
Overall survival in NRG258, a randomized phase III trial of chemo-radiation vs. chemotherapy alone for locally advanced endometrial carcinoma (LBA 5)	17
The impact of abortion restrictions on pregnant individuals with cancer in the United States: A statistical model (013)	17
Response to Letter to the Editor, Gilks et al.	17
Cervical Cancer Disparities in the American Indian/Alaska Native Population: Are Prevention Tools Being Utilized? (108)	17
Editorial board	17
Foreword	17
The rising incidence of sex cord stromal ovarian tumors in the US: Who is most at risk? (442)	17
Geographic disparities in the United States gynecologic oncology workforce: Cancer care inequities and the paradox of more docs (014)	17
Obesity-related cancers disproportionately affect women compared to men in the United States (399)	16
Telemedicine patient satisfaction metrics and methods of recurrence detection for gynecologic cancer patients throughout the initial year of the COVID-19 pandemic (515)	16
Clinical outcomes patients with high tumor mutational burden, high microsatellite stability, and mismatch repair deficiency in a multi-institutional endometrial cancer consortium (029)	16
Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Nor	16
Anti-αGal antibodies as an adjunct prognostic marker to CA-125/MUC16 in epithelial ovarian cancers	16
Lived experience of women diagnosed with a gynecologic cancer in the height of the COVID-19 pandemic in New York City (508)	16
Molecular targets and prognosis for uterine cancer: What is the role of mutations of unknown significance? (1262)	16
Social precarity as a novel framework for addressing psychosocial needs of patients with gynecologic cancers (2227)	16
Cesarean hysterectomy for placenta accreta spectrum: Temporal trends in the use of adjunct procedures	16
Frequency of actionable germline mutations identified through tumor next generation sequencing in a gynecologic cancer cohort (394)	16
Sentinel lymph node biopsy compared with systematic lymphadenectomy in patients with uterine carcinosarcoma (536)	16
System-level recommendations for improved wellness for gynecologic oncologists: A Society of Gynecologic Oncology Review	16
Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPE	16
Perioperative stress reduction in ovarian cancer (PRESERVE)	16
Beneath the layers: Association of preoperative sarcopenia with postoperative discharge destination and intensive care unit admission in patients with ovarian cancer	15
Complement C3 inhibition with pegcetacoplan controls malignant effusions in recurrent ovarian cancer: Interim results from a phase II trial	15
Hyperthermia-induced sensitization of platinum-resistant ovarian cancer cells: A potential strategy for overcoming drug resistance	15
Clinician nudge to gynecologic oncology referral at suspected ovarian cancer diagnosis: A pilot study	15
Utility of germline multi-gene panel testing in patients with endometrial cancer	15
Tranexamic acid use in advanced ovarian cancer patients undergoing cytoreductive surgery: A quality improvement study	15
Patient perspectives on palliative care in gynecologic oncology	15
Racial disparities in financial toxicity and social risks among urban endometrial cancer survivors	15
Comparative analysis of laparoscopic versus open inguinal lymphadenectomy in vulvar cancer surgery	15
Venous thromboembolism prophylaxis in gynecologic cancer patients undergoing chemotherapy	15
Trends in immune-related adverse events among patients with endometrial carcinoma	15
Is uterine serous carcinoma an exclusively postmenopausal disease? Unveiling a distinct age-specific oncologic pattern	15
Addressing dynamic physical changes during neoadjuvant chemotherapy in ovarian cancer patients through prehabilitation implementation	15
The impact of tumor size and histology on local control when utilizing high-dose-rate interstitial brachytherapy for gynecologic malignancies	14
Investigation of perturbation of DNMT and TET enzymes in endometrial cancer (308)	14
High-dose (60 Gy) intensity-modulated radiotherapy with concurrent weekly cisplatin followed by intracavitary radiation in locally advanced cervical cancer: A phase II prospective clinical trial	14
Modifiable pre-treatment factors are associated with quality of life in women with gynaecological cancers at diagnosis and one year later: Results from the HORIZONS UK national cohort study	14
Shifting trends and sicker patients: Reassessing hysterectomy performed for benign indications by gynecologic oncologists	14
ECPPF stratification identifies occult high-risk subgroups in stage I, grade 1 or 2, ≤50 % invasive endometrial cancer: Candidates for adjuvant therapy	14
Leveraging tumor multigene panel testing to identify germline variants in gynecologic cancers: A retrospective evaluation of an algorithm-based approach	14
Exosome transmit the ability of migration and invasion in heterogeneous ovarian cancer cells by regulating autophagy via targeting hsa-miR-328	14
SOLAR: Phase Ib Dose Expansion of Selumetinib (MEK Inhibitor) and OLAparib (PARP Inhibitor) Combination in Solid Tumors with RAS Pathway Alterations and in PARP Inhibitor-Resistant Ovarian Cancer (LBA	14
Phase I study of autologous T cells bearing fully-humanized chimeric antigen receptors targeting mesothelin in mesothelin- expressing cancers (314)	14
Yes, it's true: Benign hysterectomy trends for gynecologic oncologists in the United States from 2015 to 2021	14
Personalized survivorship care: Routine breast cancer risk assessment in the gynecologic oncology clinic	14
Whole exome sequencing provides loss of heterozygosity (LoH) data comparable to that of whole genome sequencing (171)	14
Impact of medicaid expansion on cervical cancer screening: A state-specific difference in difference analysis	14
Real-world outcomes of neoadjuvant chemotherapy for advanced ovarian cancer: What happens to patients who never undergo surgery?	14
Does para-aortic lymphadenectomy improve survival in pathologically diagnosed early-stage grade 3 endometrioid and non-endometrioid endometrial cancers? A retrospective cohort study in Korea and Taiwa	14
Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning	14
TERT promoter mutations and gene amplification in endometrial cancer	14
HPV clade classification is associated with response to chemoradiation in locally advanced cervical cancer	14
Similar distribution of pelvic sentinel lymph nodes and nodal metastases in cervical and endometrial cancer. A prospective study based on lymphatic anatomy	14
Editorial board	14
System-wide cost savings from standardized HPV-based cervical cancer screening in a county health system	14
Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist	13
Understanding frailty and the role of patient-centered care for older adults with gynecologic cancer	13
Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival	13
Early detection of endometrial cancer	13
Eco-responsible and rational interval debulking surgery for high-grade ovarian carcinomas: An observational, ambispective cohort study	13
Molecular diversity in uterine carcinosarcoma: Beyond TP53	13
Facilitated genetic cascade testing (FaCT): A prospective multi-institutional randomized controlled trial	13
Time to biopsy matters: Evaluating ultrasound triage and delays in endometrial cancer care	13
A phase 1/2 study of REGN5668, a MUC16 × CD28 costimulatory bispecific antibody, in combination with other targeted therapies, in patients with recurrent ovarian or endometrial cancer: Trial in progre	13
Exploring the mechanisms of resistance to trastuzumab-deruxtecan in endometrial cancer cells	13
Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma	13
Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer	13
Superparamagnetic iron oxide (SPIO) for sentinel lymph node detection in vulvar cancer	13
Autoantibody profiling of ovarian cancer patients treated with oncolytic adenovirus immunotherapy identifies novel therapeutic targets	13
Impact of the 2020 Centers for Medicare & Medicaid Services National Coverage Determination on germline testing in ovarian cancer	13
Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2- expressing solid tumors: DESTINY-PanTumor02 (DP-02) Part 1 final analysis	13
Squash the wash? Contemporary practice patterns in endometrial cancer pelvic cytology	13
Concordance between HER2 scores for primary versus recurrent tumor samples among patients with gynecologic malignancies	13
Comparison of Enhanced Recovery After Surgery (ERAS) metrics by race among gynecologic oncology patients: Ensuring equitable outcomes	13
Variation in cervical cancer screening test utilization and results in a United States-based program	13
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carc	13
Germline landscape of high grade serous ovarian cancer across age groups: Is age just a number?	13
Acute metabolic changes in response to chemotherapy among patients with ovarian cancer	13
Pelvic exenteration for debulking of advanced epithelial ovarian cancer: An NCDB analysis of survival and surgical outcomes	13
Short-term outcomes of arterial embolization in gynecologic oncology patients	13
Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial	13
Brazilian women's knowledge of cervical cancer and its prevention practices	13
Intraperitoneal therapy with engineered Newcastle disease virus encoding interleukin-12 in combination with PD-1 blockade for ovarian cancer	12
Identifying the molecular landscape of high risk uterine cancers: What mutations are most targetable? (1306)	12